THE REFILL: Latest Dosage of Patent Abuse

WHAT YOU NEED TO KNOW

  • Have You Heard? The Coalition Against Patent Abuse (CAPA) is Fighting Against Anti-Competitive Tactics Used by Some Major Pharmaceutical Companies to Keep Competition Out, Prices High. In a mini-series called, “Spot-On Savings,” CAPA outlined how the U.S. Patent and Trademark Office (USPTO), through its inter partes review (IPR) process, can generate savings for millions of American patients and the federal government. So far, CAPA has examined how the IPR process has selectively but successfully struck down bad patents in order to enable competition and dramatically lower prices for critical medications and treatments for diabetes, prostate cancer, opioid addiction, heart disease, and ulcerative colitis. 

Stay Tuned for the Final Post in this Mini-Series Here

WHAT YOU SHOULD BE READING:

The Hill: New Alzheimer’s Drug Sparks Backlash Over FDA, Pricing
Nathaniel Weixel   

  • The approval of a new Alzheimer’s drug has sparked a fierce backlash amid concerns about both price and its effectiveness. The Biogen drug, marketed under the name Aduhelm, is the first Alzheimer’s treatment approved in nearly 20 years. Yet it comes at a massive cost of $56,000 a year per patient, which is likely to renew pressure on Congress and the Biden administration to pass drug pricing reform legislation.

Bloomberg Law: Divisive Drug Patent Proposal From Trump Era Is On Biden Agenda
Susan Decker & Ian Lopez

  • The Biden administration is forging ahead with a divisive, Trump-era regulatory proposal that would limit the government’s ability to control prices on drugs developed from federally funded research. The National Institute of Standards and Technology set an October deadline to update the Bayh-Dole Act, the 1980 law that enables universities to retain patent rights on inventions discovered from government-funded research.

Kaiser Family Foundation: FDA’s Approval Of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications For Medicare And Beneficiaries
Juliette Cubanski & Tricia Neuman

  • The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S.—and now we’re about to find out. After a nearly 20-year dry spell in new treatments for Alzheimer’s disease, the Food and Drug Administration (FDA) just approved a new Alzheimer’s medication, Aduhelm (aducanumab), developed by Biogen, with an expected annual price tag of $56,000.

Bloomberg Government: Fight For Orphan Drug Bill Shows Hard Road For Taking On Pharma
Alex Ruoff

  • Legislation meant to prevent drugmakers from blocking new opioid addiction treatment medicines from coming to market faces tough prospects in the Senate this year, even though advocates say it’s a layup for lawmakers. The bill (H.R. 1629) looks to fix an issue in the nation’s orphan drug development rules that was exploited largely by one company, Indivior Plc, for a blockbuster opioid treatment. Supporters say it’s hard to argue against clearing the way for addiction treatment medicines as overdose deaths rise.

WHAT WE’RE SHARING